EAM
KRYS icon

Eventide Asset Management’s Krystal Biotech KRYS Stock Holding History

Eventide Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-95,781
Closed -$17.3M – 245
2025
Q1 		$17.3M Hold
95,781
– – 0.34% 95
2024
Q4 		$15M Hold
95,781
– – 0.27% 112
2024
Q3 		$17.4M Sell
95,781
-40,704
-30% -$7.85M 0.3% 97
2024
Q2 		$25.1M Hold
136,485
– – 0.43% 76
2024
Q1 		$24.3M Hold
136,485
– – 0.38% 81
2023
Q4 		$16.9M Buy
+136,485
New +$15.1M 0.28% 95

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Eventide Asset Management's KRYS Position: Q2 2025 in Review

Eventide Asset Management sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 95,781 shares — an estimated $17.3M sold.

Eventide Asset Management first reported a position in KRYS in Q4 2023 and held it in 6 quarters. The position peaked at $25.1M in Q2 2024. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Eventide Asset Management reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Eventide Asset Management sold 95,781 Krystal Biotech shares in Q2 2025, an estimated $17.3M.
  • Eventide Asset Management first reported a position in Krystal Biotech in Q4 2023 and held it in 6 quarters.
  • Eventide Asset Management's Krystal Biotech position peaked at $25.1M in Q2 2024.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Eventide Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.